Inclusion Criteria:

          -  Pathologically confirmed advanced or metastatic malignancy characterized by one or
             more of the following:

               -  Subject is intolerant of standard therapy

               -  Malignancy is refractory to standard therapy

               -  Malignancy relapsed after standard therapy

               -  Malignancy for which there is no standard therapy that improves survival by at
                  least 3 months.

          -  Subjects must have evaluable tumor(s) with documented alteration(s) in potential
             lucitanib related biomarker(s) VEGFR, FGFR, PDGFR.

          -  Laboratory function within specified parameters:

               -  Adequate bone marrow function: absolute neutrophil count ≥ 1,500/mL; hemoglobin ≥
                  8.5 g/dL, platelets ≥ 75,000/mL.

               -  Adequate liver function: transaminases (AST/ALT) and alkaline phosphatase ≤ 3 (≤
                  5 X ULN in the setting of liver metastasis) x ULN; bilirubin ≤ 1.5 x ULN.

               -  Adequate renal function: creatinine clearance ≥ 40 mL/min (Cockcroft Gault).

               -  Adequate blood coagulation: international normalized ratio (INR) ≤ 2.3.

               -  Serum amylase and lipase ≤ 1.5 x ULN.

          -  Adequately controlled blood pressure (BP): BP ≤ 150/90 mm Hg. Use of > 2
             antihypertensive agents at enrollment is not allowed.

          -  Adequate performance status: Eastern Cooperative Oncology Group (ECOG) 0-2

          -  Subjects must be off other anti-tumor agents for at least 5 half lives of the agent or
             4 weeks from the last day of treatment, whichever is shorter. Endocrine therapies
             (e.g., for breast or prostate cancer) and anti-Her2 therapies (for example,
             trastuzumab, pertuzumab, or lapatinib) are allowed to continue while on this study.
             Bisphosphonates or denosumab are allowed for subjects with bone metastasis.

          -  Subjects may not be receiving any other experimental agents or agents that are not FDA
             approved.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Uncontrolled hypertension (defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with
             optimized antihypertensive therapy)

          -  Subjects who have not recovered from toxicities as a result of prior anticancer
             therapy, except alopecia and infertility. Recovery is defined as < Grade 2 severity
             per Common Terminology Criteria for Adverse Events Version 4.3.

          -  Significant cardiovascular impairment: history of CHF greater than New York Heart
             Association (NYHA) Class II, unstable angina, MI or stroke within 6 months of the
             first dose of study drug, or cardiac arrhythmia requiring medical treatment.

          -  Uncontrolled hypothyroidism defined as serum TSH higher than 5 mIU/mL while receiving
             appropriate thyroid hormone therapy.

          -  Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR
             monitoring, e.g., warfarin or similar agents. Treatment with LMWH and factor X
             inhibitors that do not require INR monitoring is permitted. Anti-platelet agents are
             prohibited throughout the study.

          -  Current treatment with any prohibited medications associated with prolongation of QT
             interval.

          -  Received strong inhibitors of CYP2C8 or CYP3A4 or strong inducers of CYP3A4 ≤ 7 days
             prior to first dose of lucitanib or have on-going requirements for these medications.

          -  Received bevacizumab < 3 months prior to first dose of lucitanib.

          -  Major surgery (not including placement of central lines) within 3 weeks prior to study
             or planned surgery during the course of this study.

          -  Subjects with breast or lung cancer who are eligible for other clinical trials of
             lucitanib open at their institution are not eligible for this trial.